John Ramunas and Glenn Markov lead Rejuvenation Technologies in its pursuit to treat age-related conditions. Their product, RTI-LIV, targets Compensated Cirrhosis, aiming to utilize telomere extension as a therapeutic approach against aging.
The opinions expressed in interviews or commentary in articles appearing on this site are those of the subject or subjects and do not necessarily reflect the views of LEAF/Lifespan.io, its directors, officers or employees.